273 related articles for article (PubMed ID: 9569042)
1. Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.
Yoong KF; Adams DH
Br J Cancer; 1998 Apr; 77(7):1072-81. PubMed ID: 9569042
[TBL] [Abstract][Full Text] [Related]
2. Morphological and functional characteristics of tumor-infiltrating lymphocytes from human colorectal cancers after stimulation with rIL-2.
Keller H; Wimmenauer S; Rahner S; Reimer P; von Kleist S; Farthmann EH
Eur Surg Res; 1995; 27(4):258-68. PubMed ID: 7649213
[TBL] [Abstract][Full Text] [Related]
3. Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.
Trentin L; Zambello R; Bulian P; Cerutti A; Milani A; Pirone E; Nitti D; Agostini C; Semenzato G
Br J Cancer; 1994 Jun; 69(6):1046-51. PubMed ID: 8198969
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease.
Matsuda M; Petersson M; Lenkei R; Taupin JL; Magnusson I; Mellstedt H; Anderson P; Kiessling R
Int J Cancer; 1995 Jun; 61(6):765-72. PubMed ID: 7790109
[TBL] [Abstract][Full Text] [Related]
5. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
6. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients.
Chen YM; Yang WK; Whang-Peng J; Tsai WY; Hung YM; Yang DM; Lin WC; Perng RP; Ting CC
J Immunother; 1997 Sep; 20(5):354-64. PubMed ID: 9336742
[TBL] [Abstract][Full Text] [Related]
7. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer.
Diederichsen AC; Zeuthen J; Christensen PB; Kristensen T
Eur J Cancer; 1999 May; 35(5):721-6. PubMed ID: 10505031
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours.
Lee RS; Schlumberger M; Caillou B; Pages F; Fridman WH; Tartour E
Eur J Cancer; 1996 Jun; 32A(7):1233-9. PubMed ID: 8758259
[TBL] [Abstract][Full Text] [Related]
10. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
11. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
12. Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies.
Nouri AM; dos Santos AV; Crosby D; Oliver RT
Br J Cancer; 1991 Dec; 64(6):996-1000. PubMed ID: 1764393
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
14. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.
Kopecký O; Lukesová S; Vroblová V; Vokurková D; Morávek P; Safránek H; Hlávková D; Soucek P
Acta Medica (Hradec Kralove); 2007; 50(3):207-12. PubMed ID: 18254275
[TBL] [Abstract][Full Text] [Related]
15. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
Yang SC; Fry KD; Grimm EA; Roth JA
J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.
Maeurer MJ; Walter W; Martin D; Zitvogel L; Elder E; Storkus W; Lotze MT
Scand J Immunol; 1997 Feb; 45(2):182-92. PubMed ID: 9042431
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer.
Michael-Robinson JM; Pandeya N; Walsh MD; Biemer-Huttmann AE; Eri RD; Buttenshaw RL; Lincoln D; Clouston AD; Jass JR; Radford-Smith GL
J Pathol; 2006 Feb; 208(3):381-7. PubMed ID: 16315333
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients.
Whitford P; George WD; Campbell AM
Cancer Lett; 1992 Jan; 61(2):157-64. PubMed ID: 1730139
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
